Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Munster – page 14

701 clinical trials in Munster, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Munster at a glance
701
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

701 trials in Munster

Open in trial search

T-cell type acute leukaemia

Recruiting

Study on the Safety and Effectiveness of Isatuximab and Drug Combination for Adults with Relapsed or Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Goethe University Frankfurt

Neovascular age-related macular degeneration

Recruiting

Study on Long-Term Safety of Ranibizumab for Patients with Wet Age-Related Macular Degeneration Using a Port Delivery System

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:F. Hoffmann-La Roche AG

Acute lymphocytic leukaemia

Recruiting

Study Comparing Inotuzumab Ozogamicin to Drug Combination for Children with High-Risk Relapsed B-cell Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Crisantaspase
  • Sponsor:Pfizer Inc.

Diffuse large B-cell lymphoma

Recruiting

Study on High-Dose Chemotherapy with Cytarabine and Drug Combination for Elderly Patients with Primary CNS Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:65+ years
  • Substances:Busulfan
  • Sponsor:Medical Center - University Of Freiburg

Ovarian epithelial cancer

Recruiting

Study on Letrozole Maintenance Therapy for Patients with Epithelial Ovarian Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Swiss GO Trial Group

Acute myeloid leukaemia

Recruiting

Study of Gilteritinib, Venetoclax, and Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutations Not Eligible for Intensive Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Technische Universitat Dresden

Factor VIII deficiency

Recruiting

Study on Emicizumab and Drug Combination for Patients with Haemophilia A and FVIII Inhibitors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:Emory University

Lymphangiosarcoma+34

Recruiting

Study of trabectedin alone versus trabectedin with tTF-NGR combination therapy in adults with metastatic or refractory soft tissue sarcoma who failed first-line treatment

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ttf-Ngr
  • Sponsor:Universitaet Muenster

Medulloblastoma

Recruiting

Study on Medulloblastoma Treatment in Children Aged 3-5 Using Carboplatin and Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:University Medical Center Hamburg-Eppendorf

Psoriatic arthropathy+1

Recruiting

Study on the Safety and Immune Response of Shingrix Vaccine in Patients with Psoriasis or Psoriatic Arthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Recombinant Varicella Zoster Virus Glycoprotein E
  • Sponsor:Justus-Liebig-Universitaet Giessen

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Bortezomib
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Breast cancer

Recruiting

Study on the Effectiveness and Safety of Saruparib and Camizestrant in Adults with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Munster

What the registry says about research in the country

01 Oncology & Hematology

Advanced research focusing on lymphoma treatments and innovative therapies for breast cancer and lung cancer. Studies include evaluations of new combinations of targeted therapies and immunotherapy approaches.

  • Diffuse Large B-Cell Lymphoma
  • Advanced Breast Cancer
  • Non-Small Cell Lung Cancer
  • Acute Myeloid Leukemia

Several trials are exploring novel treatment combinations and maintenance therapies for various blood cancers.

02 Metabolic & Cardiovascular Disorders

Comprehensive studies addressing obesity management and cardiovascular disease prevention. Research includes innovative approaches for weight management and heart failure risk reduction.

  • Obesity Treatment
  • Type 2 Diabetes
  • Heart Failure Prevention
  • Cardiovascular Risk Management

Multiple trials are investigating new therapeutic options for weight management and cardiovascular health improvement.

03 Dermatology & Immunology

Innovative research in treating chronic skin conditions including plaque psoriasis and hidradenitis suppurativa. Studies focus on novel biological therapies and targeted treatments.

  • Moderate to Severe Plaque Psoriasis
  • Hidradenitis Suppurativa
  • Chronic Rhinosinusitis

Trials are evaluating next-generation treatments for inflammatory skin conditions and immune-mediated disorders.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.